Dermira Inc. (NASDAQ:DERM) Director William R. Ringo sold 500 shares of the firm’s stock in a transaction that occurred on Monday, October 3rd. The shares were sold at an average price of $34.25, for a total value of $17,125.00. Following the completion of the transaction, the director now owns 500 shares of the company’s stock, valued at approximately $17,125. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.
Dermira Inc. (NASDAQ:DERM) opened at 34.76 on Monday. Dermira Inc. has a 52 week low of $17.42 and a 52 week high of $36.16. The stock’s market cap is $1.23 billion. The firm’s 50-day moving average price is $33.30 and its 200-day moving average price is $29.61.
Dermira (NASDAQ:DERM) last issued its quarterly earnings results on Monday, August 8th. The biopharmaceutical company reported ($0.89) earnings per share for the quarter, missing the consensus estimate of ($0.86) by $0.03. Equities analysts predict that Dermira Inc. will post ($3.46) earnings per share for the current fiscal year.
Several large investors have recently modified their holdings of DERM. Strs Ohio increased its stake in shares of Dermira by 72.6% in the second quarter. Strs Ohio now owns 12,600 shares of the biopharmaceutical company’s stock valued at $368,000 after buying an additional 5,300 shares during the last quarter. Eagle Asset Management Inc. increased its stake in shares of Dermira by 4.3% in the second quarter. Eagle Asset Management Inc. now owns 1,344,721 shares of the biopharmaceutical company’s stock valued at $39,333,000 after buying an additional 55,991 shares during the last quarter. Hamilton Lane Advisors LLC increased its stake in shares of Dermira by 179.5% in the second quarter. Hamilton Lane Advisors LLC now owns 34,615 shares of the biopharmaceutical company’s stock valued at $1,099,000 after buying an additional 22,229 shares during the last quarter. Sphera Funds Management LTD. acquired a new stake in shares of Dermira during the first quarter valued at $2,482,000. Finally, Geode Capital Management LLC increased its stake in shares of Dermira by 7.8% in the first quarter. Geode Capital Management LLC now owns 123,424 shares of the biopharmaceutical company’s stock valued at $2,552,000 after buying an additional 8,952 shares during the last quarter. Hedge funds and other institutional investors own 82.46% of the company’s stock.
A number of research firms have recently commented on DERM. Zacks Investment Research upgraded Dermira from a “sell” rating to a “hold” rating in a research note on Tuesday, June 14th. Needham & Company LLC restated a “positive” rating and issued a $46.00 target price on shares of Dermira in a research note on Monday, October 3rd. Finally, Leerink Swann restated a “buy” rating on shares of Dermira in a research note on Wednesday, October 5th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $41.00.
Dermira Company Profile
Dermira, Inc is a biopharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated therapies for dermatologic diseases. The Company’s portfolio includes three late-stage product candidates that target unmet needs and market opportunities, such as Cimzia (certolizumab pegol), DRM04 and DRM01.
Receive News & Ratings for Dermira Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira Inc. and related companies with MarketBeat.com's FREE daily email newsletter.